Bichet, Daniel GDaniel GBichetHopkin, Robert JRobert JHopkinAguiar, PatrícioPatrícioAguiarAllam, Sridhar RSridhar RAllamYIN-HSIU CHIENGiugliani, RobertoRobertoGiuglianiKallish, StaciStaciKallishKineen, SabinaSabinaKineenLidove, OlivierOlivierLidoveNiu, Dau-MingDau-MingNiuOlivotto, IacopoIacopoOlivottoPolitei, JuanJuanPoliteiRakoski, PaulPaulRakoskiTorra, RoserRoserTorraTøndel, CamillaCamillaTøndelHughes, Derralynn ADerralynn AHughes2023-10-312023-10-3120232296-858Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/636690Fabry disease is a progressive disorder caused by deficiency of the α-galactosidase A enzyme (α-Gal A), leading to multisystemic organ damage with heterogenous clinical presentation. The addition of the oral chaperone therapy migalastat to the available treatment options for Fabry disease is not yet universally reflected in all treatment guidelines. These consensus recommendations are intended to provide guidance for the treatment and monitoring of patients with Fabry disease receiving migalastat.enalpha-galactosidase A; amenability; chaperone therapy; globotriaosylsphingosine; patient journey; treatment decisionsjournal article10.3389/fmed.2023.1220637377277612-s2.0-85171321636https://api.elsevier.com/content/abstract/scopus_id/85171321636